CLINICAL TRIALS PROFILE FOR MERESTINIB
✉ Email this page to a colleague
Clinical Trials for Merestinib
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02711553 ↗ | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | Active, not recruiting | Eli Lilly and Company | Phase 2 | The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer. |
| NCT02745769 ↗ | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | Completed | Eli Lilly and Company | Phase 1 | The main purpose of this study is to evaluate the safety of ramucirumab in combination with other targeted agents in participants with advanced cancers. |
| NCT02779738 ↗ | A Study of Merestinib (LY2801653) in Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | The purpose of this study is to evaluate the effect of food on merestinib (standard meal and high-fat meal) compared to the fasted state. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. In addition, the tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected. The study will last approximately 28 days. Screening is required within 28 days prior to the start of the study. |
| NCT02791334 ↗ | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Active, not recruiting | Eli Lilly and Company | Phase 1 | The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors. |
| NCT02920996 ↗ | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | Active, not recruiting | Eli Lilly and Company | Phase 2 | This research study is examining merestinib (a targeted therapy) as a possible treatment for non-small cell lung cancer (NSCLC) that was found to have a specific change in the MET gene (a MET exon 14 mutation); or as a treatment for solid tumors that have an alteration in the NTRK gene (an NTRK1, 2, or 3 rearrangement). |
| NCT02920996 ↗ | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | Active, not recruiting | Dana-Farber Cancer Institute | Phase 2 | This research study is examining merestinib (a targeted therapy) as a possible treatment for non-small cell lung cancer (NSCLC) that was found to have a specific change in the MET gene (a MET exon 14 mutation); or as a treatment for solid tumors that have an alteration in the NTRK gene (an NTRK1, 2, or 3 rearrangement). |
| NCT03027284 ↗ | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | Completed | Eli Lilly and Company | Phase 1 | The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Merestinib
Condition Name
Clinical Trial Locations for Merestinib
Trials by Country
Clinical Trial Progress for Merestinib
Clinical Trial Phase
Clinical Trial Sponsors for Merestinib
Sponsor Name
